Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
about
Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of MethodsEconomic impact of biologic utilization patterns in patients with psoriatic arthritisDose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease.Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid populationIncremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data.Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis.Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveTapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting.Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic.Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort StudySystematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.Biologics in oral medicine: principles of use and practical considerations.When is switching warranted among biologic therapies in rheumatoid arthritis?Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.Cost of arthritis: a systematic review of methodologies used for direct costs.Factors associated with higher healthcare costs in individuals living with arthritis: evidence from the quantile regression approach.The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification.Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
P2860
Q28069373-7FC14C7E-C748-4145-A94B-BABB2F30BAF1Q33840422-9A4ED072-7F47-4AAC-BD1E-31599D2DF3CAQ33870043-74F00B44-605F-450C-BE0A-60309D12B503Q34079261-E0A24CAB-3FF1-433D-BC14-ABE401526DF4Q34211985-6CD412A9-F8FA-411E-9A3E-61961331E34AQ34311262-6C74E690-278B-4A4E-B39E-D537619A4081Q35001257-E30117E4-74BC-4270-B4B2-D28457022939Q35851000-C5B63A0A-A04E-4CEC-95A1-5A2255D222FDQ36274355-7E5A7942-F9CA-4161-BA12-88B8BC743366Q36439036-D4E3308F-ECFC-4071-9249-4580AAB760D7Q36543127-E43A09BA-E3E5-440E-BD30-9E8D58951B80Q36923598-CBA9FBB3-30DD-4646-957E-06A907355CBBQ36942874-4FE03B7A-D9B1-4FBB-896D-1A9DFF881095Q37143744-E92AA517-306A-49F4-B888-EBED89DE93B5Q37452967-26674CC3-F50E-4611-890C-66650F682890Q37567461-C9476D1C-A8F0-4E7A-B84A-BA860FF3B9A8Q37992954-1F39C86C-4F1C-4258-BEDF-1A93C133ABEEQ37993932-735C8313-2747-4FFA-A7DF-534D1E713954Q38027571-4B8FE50F-2BE9-4FA6-A348-5B0BE63E3DB9Q38320157-4B51DE4D-9576-42CA-A78F-6B079A8A1EE1Q38338700-00B7E770-D265-49B4-AA16-363E5A2D3E47Q38652998-E8336293-9372-427B-B0D3-7342379A7621Q39015806-C3790F0C-4D1E-41FB-B0C9-A5D61F362F96Q40942139-B5FBC404-CEE8-4F55-B8AA-A2A0A66F47B8Q42289113-9E6397BB-B632-4921-9631-EE229FE82A47Q44790776-210F5FFB-9AFD-4ADF-98E9-14645D907883Q47308760-0FD30EFE-7162-4045-A760-F3E2BB806035Q53119214-B4C6DA5A-3796-4C9C-8367-AD981E839037
P2860
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Differences in annual medicati ...... in a managed care population.
@en
Differences in annual medicati ...... in a managed care population.
@nl
type
label
Differences in annual medicati ...... in a managed care population.
@en
Differences in annual medicati ...... in a managed care population.
@nl
prefLabel
Differences in annual medicati ...... in a managed care population.
@en
Differences in annual medicati ...... in a managed care population.
@nl
P2093
P1476
Differences in annual medicati ...... in a managed care population.
@en
P2093
Daniel A Ollendorf
David Klingman
Elisabeth Hazard
Saurabh Ray
P304
P356
10.1016/J.CLINTHERA.2009.04.002
P577
2009-04-01T00:00:00Z